Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

Stopped early · Phase 4

Conditions studied: Human Immunodeficiency Virus

In brief

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COB/FTC/TAF) is a coformulated STR, is the only protease inhibitor based STR, and is noted for its high tolerability3. These traits have the potential to improve adherence in patients who have intolerance to the integrase inhibitor class. We propose a two part study design to evaluate if patients who have suboptimal adherence due to integrase inhibitor intolerance may better tolerate Symtuza and subsequently have improved adherence.

Key facts

Study ID

NCT04240210

Run by

Midland Research Group, Inc.

People needed

1

Starts

2019-09-17

Expected to finish

2021-12-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• ≥ 18 years of age.
• HIV positive receiving ART of any type.
• Currently on an integrase containing regimen AND Reports non-adherent due to medication intolerance.
• GFR≥30mL/min.
• AST/ALT ≤ 3 times upper limit of normal. (AST- U/L 10-40), (ALT- U/L 9-46)
• Total bilirubin of ≤1.5 mg/dL.

You may not qualify if…

• Known resistance to darunavir or tenofovir
• Known intolerance to Symtuza or its components
• Current pregnancy
• Requires continued use of any of the agents in table 6.2.3.2.4
• Cirrhosis, regardless of compensation status
• Active, serious infections within 30 days of baseline
• History of malignancy within 5 years of baseline, except cutaneous Kaposi's sarcoma, basal cell or resected non-invasive cutaneous squamous cell carcinoma
• Life expectancy of less than a year
• Participation in any other investigation study 30 days prior to enrollment

Where it is running

• Midland Research Group, Inc — Oakland Park, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.